PI3K/AKT/mTOR信号通路在三阴乳腺癌靶向治疗中的研究进展OA
Research Progress of PI3K/AKT/mTOR Signaling Pathway in Targeted Therapy for Triple-negative Breast Cancer
三阴乳腺癌(TNBC)为乳腺癌重要亚型,因其三阴性特点导致分子靶向治疗效果较差,临床多采用新辅助化疗治疗TNBC,但疗效一般,预后差.磷脂酰肌醇 3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶点(PI3K/AKT/mTOR)信号通路及解聚素-金属蛋白酶 17(ADAM17)在多种肿瘤中都出现异常激活状态,是抗肿瘤的重要靶点.本文结合近年来相关文献,对PI3K/AKT/mTOR信号通路及ADAM17在肿瘤发生中的作用机制、相关靶点及TNBC靶向治疗中的研究进行汇总与分析,以期为多靶点联合治疗TNBC提供新思路.
Triple-negative breast cancer(TNBC)is an important subtype of breast cancer,because of its triple-negative characteristics,the molecular targeted therapy effect is poor,and neoadjuvant chemotherapy is used in the clinic to treat TNBC,but the efficacy is general and the prognosis is poor.The phosphatidylositol 3-kinase/protein kinase B/mammalian rapamycin target(PI3K/AKT/mTOR)signaling pathway,and depolymer-metalloproteinase 17(ADAM17)have abnormal activation states in a variety of tumors and are important anti-tumor targets.In this paper,combined with the relevant literature in recent years,the research on the PI3K/AKT/mTOR signaling pathway,and ADAM17 in tumorigenesis,related targets and TNBC targeted therapy is summarized and analyzed,in order to provide new ideas for the multi-target combination therapy of TNBC.
杨冠楠;张雪鹏
华北理工大学附属医院肿瘤外科 河北 唐山 063000
磷脂酰肌醇3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶点信号通路解聚素-金属蛋白酶17三阴乳腺癌靶向治疗
PI3K/AKT/mTOR signaling pathwayDepolymerin-metalloproteinase 17Triple-negative breast cancerTargeted therapy
《中国医学创新》 2024 (001)
155-158 / 4
评论